Cancer Therapy News and Research

RSS

Experts applaud the EU Presidency for establishing a transatlantic task force to address antibiotic resistance

Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide.

7 Nov 2009

Bioniche Life Sciences announces financial results for its Fiscal 2010 first-quarter

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 first quarter, ended September 30, 2009.

6 Nov 2009

New biosensor device may help in combating cancer

A powerful new biosensor developed by European researchers will help identify cells in the immune system that actively suppress tumour growth, then put them to use. Enlisting the patient's own immune system would be like sending reinforcements for resistance fighters.

5 Nov 2009

Oncolytics Biotech reports financial results for the third quarter of 2009

Oncolytics Biotech Inc. today announced its financial results for the three and nine-month periods ended September 30, 2009.

5 Nov 2009

American Shared Hospital Services reports financial results for the third quarter of 2009

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the third quarter and first nine months of 2009.

5 Nov 2009

Cancer patients want strong relationship with their radiation oncologist

What do patients want from their radiation oncologists? The most significant preference is that more than one-third of female cancer patients (37 percent) prefer to have their hands held by their radiation oncologists during important office visits, compared to 12 percent of men, according to a randomized study presented November 4, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

4 Nov 2009

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively guide prostate cancer therapy targeting and dosing and is a significant predictor of disease free survival, according to data presented on Tuesday, November 3, 2009 at the 51st American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting in Chicago, Illinois.

4 Nov 2009

MagForce Nanotechnologies completes clinical trial of Nano-Cancer therapy in glioblastoma patients

MagForce Nanotechnologies AG has successfully completed its single-arm clinical trial on the efficacy of thermotherapy using superparamagnetic nanoparticles in patients with recurrent glioblastoma.

4 Nov 2009

MagForce Nanotechnologies announces successful completion of its Nano-Cancer therapy trials

MagForce Nanotechnologies AG, the Berlin-based medical technology company majority owned by Nanostart AG, today announced the successful completion of final trials demonstrating the efficacy of its Nano-Cancer® therapy in patients with recurrent glioblastoma, a frequent form of brain tumor which is highly malignant. The actual study results significantly exceeded the study objective.

4 Nov 2009

Aethlon Medical begins collaborative biomarker program to study neurodegenerative disease

Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that it has initiated a collaborative biomarker discovery program with the Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine and the Sports Legacy Institute (SLI).

3 Nov 2009

SBRT stops the growth of cancer for 98% of patients with NSCLC

Stereotactic body radiation therapy (SBRT) stopped the growth of cancer at its original site in the lung for three years among nearly 98 percent of patients with early non-small cell lung cancer (NSCLC) who are unable to have the cancer surgically removed, according to an updated three-year study presented November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

3 Nov 2009

World-record energies for laser accelerated particles achieved

An international team of physicists at Los Alamos National Laboratory has succeeded in using intense laser light to accelerate protons to energies never before achieved. Using this technique, scientists can now accelerate particles to extremely high velocities that would otherwise only be possible using large accelerator facilities. Physicists around the world are examining laser particle acceleration and laser produced radiation for potential future uses in cancer treatment.

3 Nov 2009

Tumor-penetrating microparticles may offer treatment hope for those suffering with pancreatic cancer

Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein.

3 Nov 2009

BioVex publishes OncoVEX (GM-CSF) Phase 2 study results

BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO). The previously announced top line results report a high objective durable response rate and a high complete response rate, combined with a relatively benign side effect profile.

2 Nov 2009

Blue Cross Blue Shield of Michigan, OPR launch an innovative oncology treatment initiative

Blue Cross Blue Shield of Michigan and Oncology Physician Resource announced today the launch of an innovative oncology treatment initiative aimed at enhancing the quality of care for patients with certain types of cancer.

2 Nov 2009

Bioengineers develop nano-delivery system for cancer therapy

Going smaller could bring better results, especially when it comes to cancer-fighting drugs.

2 Nov 2009

Hospitals and medical centers partner to share quality data to improve breast cancer treatment

The Metropolitan Chicago Breast Cancer Task Force has announced the 56 participating hospitals, medical centers and mammography providers that are partnering to share quality data in order to identify deficits and implement strategies to improve breast cancer screening and treatment and reduce breast cancer mortality disparities.

31 Oct 2009

GE Healthcare to showcase its sophisticated imaging systems for oncology at the ASTRO meeting

According to the American Cancer Society, more than one million people are diagnosed with cancer each year. In the United States, about 1 out of every 2 men and 1 out of every 3 women will have some type of cancer at some point during their lifetime. The sooner a cancer is detected and treatment begins, the better the patient’s chances for survival.

31 Oct 2009

BHGI's approach to cancer treatment guidelines for low- and moderate-income countries

When the prestigious British medical journal The Lancet Oncology this week published six cancer treatment guideline papers aimed at the resource-diverse nations of Asia, it used as its model the economic template developed by the Breast Health Global Initiative (BHGI) based at Fred Hutchinson Cancer Research Center.

31 Oct 2009

Updated results from Oncolytics Biotech's Phase II study of REOLYSIN presented at CTOS meeting

Oncolytics Biotech Inc. announced that a poster presentation covering updated results of a Phase II study of REOLYSIN(R) administered intravenously to patients with sarcomas metastatic to the lung will be presented at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting being held in Miami Beach, Florida on November 6th, 2009.

30 Oct 2009

Cancer Therapy News and Research

Experts applaud the EU Presidency for establishing a transatlantic task force to address antibiotic resistance

Bioniche Life Sciences announces financial results for its Fiscal 2010 first-quarter

New biosensor device may help in combating cancer

Oncolytics Biotech reports financial results for the third quarter of 2009

American Shared Hospital Services reports financial results for the third quarter of 2009

Cancer patients want strong relationship with their radiation oncologist

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

MagForce Nanotechnologies completes clinical trial of Nano-Cancer therapy in glioblastoma patients

MagForce Nanotechnologies announces successful completion of its Nano-Cancer therapy trials

Aethlon Medical begins collaborative biomarker program to study neurodegenerative disease

SBRT stops the growth of cancer for 98% of patients with NSCLC

World-record energies for laser accelerated particles achieved

Tumor-penetrating microparticles may offer treatment hope for those suffering with pancreatic cancer

BioVex publishes OncoVEX (GM-CSF) Phase 2 study results

Blue Cross Blue Shield of Michigan, OPR launch an innovative oncology treatment initiative

Bioengineers develop nano-delivery system for cancer therapy

Hospitals and medical centers partner to share quality data to improve breast cancer treatment

GE Healthcare to showcase its sophisticated imaging systems for oncology at the ASTRO meeting

BHGI's approach to cancer treatment guidelines for low- and moderate-income countries

Updated results from Oncolytics Biotech's Phase II study of REOLYSIN presented at CTOS meeting

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News